← Leaderboards
Desmond Arthur Schatz
University Of Florida
$16,657,017
Attributed
$17,227,497
Total exposure
48
Grants
32
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.2M · FY2005–25$2.5M$1.9M$1.3M$625K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$17,227,497 · 48
By mechanism
U01$11,436,092 · 4
UC4$2,842,384 · 2
M01$2,750,866 · 40
P01$183,155 · 1
R13$15,000 · 1
Top collaborators
- Kimberly Driscoll2 shared
- Matthew James Gurka2 shared
- Brandon A. Zielinski2 shared
Most similar at University Of Florida
Same institution · by research overlap
- Jin-Xiong She$30,457,921
- Michael S Okun$8,217,680
- Martha L Campbell-Thompson$8,691,417
- Angelos Barmpoutis$3,532,769
- Mark A Atkinson$38,540,675
Others in their field
Top investigators on “Insulin”
- Jeffrey P Krischer · University Of South Florida$605,714,892
- John M Lachin · George Washington University$153,440,346
- David M Nathan · Massachusetts Institute Of Technology$139,041,931
- Kathryn Hirst · Caritas St. Elizabeth'S Medical Center$108,827,660
- Mark A Magnuson · Vanderbilt University$79,749,111
- Jose A Luchsinger · Columbia University Health Sciences$71,267,462
Research focus
InsulinClinical ResearchInsulin Dependent Diabetes MellitusUnited States National Institutes Of HealthDiabetes MellitusHuman SubjectResearch PersonnelAutoantibodiesFundingPreventInsulin-Dependent Diabetes MellitusInstitutionBeta CellGrantClinical TrialsSourceResourcesComputer Retrieval Of Information On Scientific Projects DatabaseCell PhysiologyHuman Therapy EvaluationCellsFloridaNatural HistoryDiabetes Mellitus, Insulin-Dependent
Grant awards (83)
Survival and potential of insulin-deficient beta cells in type 1 diabetes$668,675
U01 · FY2025 · DK · contact PI
Diabetes Brain and Cognitive Development-Type 1 (DBCD-T1)$492,311
U01 · FY2025 · DK
Survival and potential of insulin-deficient beta cells in type 1 diabetes$684,697
U01 · FY2024 · DK · contact PI
Diabetes Brain and Cognitive Development-Type 1 (DBCD-T1)$268,329
U01 · FY2024 · DK
Survival and potential of insulin-deficient beta cells in type 1 diabetes$699,988
U01 · FY2023 · DK · contact PI
Survival and potential of insulin-deficient beta cells in type 1 diabetes$726,966
U01 · FY2022 · DK · contact PI
Non-invasive detection of cell death in type 1 diabetes: insight into novel disease mechanisms.$1,398,429
UC4 · FY2017 · DK · contact PI
TrialNet: University of Florida Clinical Center and Network$525,802
U01 · FY2017 · DK · contact PI
TrialNet: University of Florida Clinical Center and Network$525,802
U01 · FY2016 · DK · contact PI
TrialNet: University of Florida Clinical Center and Network$525,802
U01 · FY2015 · DK · contact PI
Non-Invasive Diagnosis of Human Beta Cell Damage and Death$1,443,955
UC4 · FY2014 · DK · contact PI
TrialNet: University of Florida Clinical Center and Network$687,463
U01 · FY2014 · DK · contact PI
TrialNet: University of Florida Clinical Center and Network$20,243
U01 · FY2014 · DK · contact PI
TrialNet: University of Florida Clinical Center and Network$635,979
U01 · FY2013 · DK · contact PI
TrialNet: University of Florida Clinical Center and Network$467,825
U01 · FY2012 · DK · contact PI
TrialNet: University of Florida Clinical Center and Network$613,839
U01 · FY2011 · DK · contact PI
TrialNet: University of Florida Clinical Center and Network$643,470
U01 · FY2010 · DK · contact PI
TrialNet: University of Florida Clinical Center and Network$613,004
U01 · FY2009 · DK · contact PI
TEDDY$49,651
M01 · FY2009 · RR · contact PI
NATURAL HISTORY STUDY OF THE DEVELOPMENT OF TYPE 1 DIABETES TYPE 1 TRIALNET PROT$16,783
M01 · FY2009 · RR · contact PI
CLINICAL TRIAL: EFFECTS OF RITUXIMAB ON THE PROGRESSION OF TYPE 1 DIABETES IN NE$10,110
M01 · FY2009 · RR · contact PI
NEW ONSET OF TYPE 1 DIABETES MYCOPHENOLATE MOFETIL-DACLIZUMAB CLINICAL TRIAL$9,504
M01 · FY2009 · RR · contact PI
EFFECTS OF CTLA-4 ON THE PROGRESSION OF T1D IN NEW ONSET SUBJECTS$3,640
M01 · FY2009 · RR · contact PI
ORAL INSULIN FOR PREVENTION OF DIABETES IN RELATIVES AT RISK FOR T1D MELLITUS$2,831
M01 · FY2009 · RR · contact PI
SCREENING OF NEWBORNS/CHILDREN TO IDENTIFY SUBJECTS AT HIGH RISK FOR IDD$2,224
M01 · FY2009 · RR · contact PI
TEDDY$90,077
M01 · FY2008 · RR · contact PI
CLINICAL TRIAL: EFFECTS OF RITUXIMAB ON THE PROGRESSION OF TYPE 1 DIABETES IN NE$49,862
M01 · FY2008 · RR · contact PI
NATURAL HISTORY STUDY OF THE DEV OF TYPE 1 DIAB TYPE 1 TRIALNET PROT TN-01$47,152
M01 · FY2008 · RR · contact PI
NEW ONSET OF TYPE 1 DIABETES MYCOPHENOLATE MOFETIL-DACLIZUMAB CLINICAL TRIAL$45,526
M01 · FY2008 · RR · contact PI
T CELL ASSAY VALIDATION STUDY$37,396
M01 · FY2008 · RR · contact PI
SCREENING OF NEWBORNS/CHILDREN TO IDENTIFY SUBJECTS AT HIGH RISK FOR IDD$10,297
M01 · FY2008 · RR · contact PI
TYPE 1 DIABETES GENETICS CONSORTIUM$8,130
M01 · FY2008 · RR · contact PI
ORAL INSULIN FOR PREVENTION OF DIABETES IN RELATIVES AT RISK FOR T1D MELLITUS$5,962
M01 · FY2008 · RR · contact PI
TrialNet: University of Florida Clinical Center and Network$839,958
U01 · FY2007 · DK · contact PI
NEW ONSET OF TYPE 1 DIABETES MYCOPHENOLATE MOFETIL-DACLIZUMAB CLINICAL TRIAL$96,481
M01 · FY2007 · RR · contact PI
T E D D Y$92,890
M01 · FY2007 · RR · contact PI
NATURAL HISTORY STUDY OF THE DEV OF TYPE 1 DIAB TYPE 1 TRIALNET PROT TN-01$45,560
M01 · FY2007 · RR · contact PI
9th Immunology of Diabetes Society Research Symposium$15,000
R13 · FY2007 · DK · contact PI
SCREENING OF NEWBORNS/CHILDREN TO IDENTIFY SUBJECTS AT HIGH RISK FOR IDD$13,937
M01 · FY2007 · RR · contact PI
TYPE 1 DIABETES GENETICS CONSORTIUM$4,289
M01 · FY2007 · RR · contact PI
Trialnet: Univ. of Florida Clinical Center and Network$183,093
U01 · FY2006 · DK · contact PI
TEDDY$91,269
M01 · FY2006 · RR · contact PI
NATURAL HISTORY STUDY OF THE DEV OF TYPE 1 DIAB TYPE 1 TRIALNET PROT TN-01$48,854
M01 · FY2006 · RR · contact PI
NEW ONSET OF TYPE 1 DIABETES MYCOPHENOLATE MOFETIL-DACLIZUMAB CLINICAL TRIAL$47,533
M01 · FY2006 · RR · contact PI
IMPROVING METABOLIC ASSESSMENTS IN T1DM CLINICAL TRIALS$33,669
M01 · FY2006 · RR · contact PI
TYPE 1 DIABETES GENETICS CONSORTIUM$29,708
M01 · FY2006 · RR · contact PI
SCREENING OF NEWBORNS/CHILDREN TO IDENTIFY SUBJECTS AT HIGH RISK FOR IDD$20,003
M01 · FY2006 · RR · contact PI
Trialnet: Univ. of Florida Clinical Center and Network$187,500
U01 · FY2005 · DK
SCREENING OF NEWBORNS/CHILDREN TO IDENTIFY SUBJECTS AT HIGH RISK FOR IDD$75,234
M01 · FY2005 · RR
TYPE 1 DIABETES GENETICS CONSORTIUM$20,546
M01 · FY2005 · RR
NATURAL HISTORY STUDY OF THE DEV OF TYPE 1 DIAB: TYPE 1 TRIALNET PROT TN-01$15,067
M01 · FY2005 · RR
TEDDY$9,554
M01 · FY2005 · RR
DIABETES PREVENTION TRIAL - TYPE 1$2,055
M01 · FY2005 · RR
NEW ONSET OF TYPE 1 DIABETES MYCOPHENOLATE MOFETIL-DACLIZUMAB CLINICAL TRIAL$1,370
M01 · FY2005 · RR
Trialnet: Univ. of Florida Clinical Center and Network$272,057
U01 · FY2004 · DK
Screening of Newborns/children To Identify Subjects at High Risk for IDD$151,973
M01 · FY2004 · RR
Diabetes Prevention Trial - Type 1$54,664
M01 · FY2004 · RR
Trialnet: Univ. of Florida Clinical Center and Network$267,004
U01 · FY2003 · DK
Trialnet: Univ. of Florida Clinical Center and Network$280,049
U01 · FY2002 · DK
Trialnet: University of Florida Clinical Center$606,236
U01 · FY2001 · DK
ISLET CELL AUTOANTIBODIES AND THE NATURAL HISTORY OF INSULIN DEPENDENT DIABETES$207,281
M01 · FY2001 · RR
FEASIBILITY OF ORAL INSULIN THERAPY TO DELAY BETA CELL DESTRUCTION IN NEWLY IDDM$207,281
M01 · FY2001 · RR
DIABETES PREVENTION TRIAL--TYPE 1$207,281
M01 · FY2001 · RR
ADMINISTRATION OF SUBCUTANEOUS INSULIN TO PREVENT IDD IN HIGH RISK NONRELATIVES$207,281
M01 · FY2001 · RR
USE OF SUBCUTANEOUS INSULIN TO PREVENT INSULIN DEPENDENT DIABETES$207,281
M01 · FY2001 · RR
ADMINISTRATION OF SUBCUTANEOUS INSULIN TO PREVENT IDD IN HIGH RISK NONRELATIVES$55,741
M01 · FY2001 · RR
FEASIBILITY OF ORAL INSULIN THERAPY TO DELAY BETA CELL DESTRUCTION IN NEWLY IDDM$55,741
M01 · FY2001 · RR
DIABETES PREVENTION TRIAL--TYPE 1$55,741
M01 · FY2001 · RR
ISLET CELL AUTOANTIBODIES AND THE NATURAL HISTORY OF INSULIN DEPENDENT DIABETES$55,741
M01 · FY2001 · RR
USE OF SUBCUTANEOUS INSULIN TO PREVENT INSULIN DEPENDENT DIABETES$55,741
M01 · FY2001 · RR
IMMUNE FUNCTION AND GENETIC SUSCEPTIBILITY FOR IDD$183,155
P01 · FY2000 · AI
FEASIBILITY OF ORAL INSULIN THERAPY TO DELAY BETA CELL DESTRUCTION IN NEWLY IDDM$38,391
M01 · FY2000 · RR
ISLET CELL AUTOANTIBODIES AND THE NATURAL HISTORY OF INSULIN DEPENDENT DIABETES$38,391
M01 · FY2000 · RR
DIABETES PREVENTION TRIAL--TYPE 1$38,391
M01 · FY2000 · RR
ADMINISTRATION OF SUBCUTANEOUS INSULIN TO PREVENT IDD IN HIGH RISK NONRELATIVES$38,391
M01 · FY2000 · RR
USE OF SUBCUTANEOUS INSULIN TO PREVENT INSULIN DEPENDENT DIABETES$38,391
M01 · FY2000 · RR
FEASIBILITY OF ORAL INSULIN THERAPY TO DELAY BETA CELL DESTRUCTION IN NEWLY IDDM$0
M01 · FY2000 · RR
USE OF SUBCUTANEOUS INSULIN TO PREVENT INSULIN DEPENDENT DIABETES$0
M01 · FY2000 · RR
ACTIVITY/IMMUNOGENETICS--DPT1 W/ ANTI ISLET AUTOANTIBODY$0
M01 · FY2000 · RR
ACTIVITY/IMMUNOGENETICS--DPT1 W/ ANTI ISLET AUTOANTIBODY$0
M01 · FY2000 · RR
ISLET CELL AUTOANTIBODIES AND THE NATURAL HISTORY OF INSULIN DEPENDENT DIABETES$0
M01 · FY2000 · RR
DIABETES PREVENTION TRIAL--TYPE 1$0
M01 · FY2000 · RR
ADMINISTRATION OF SUBCUTANEOUS INSULIN TO PREVENT IDD IN HIGH RISK NONRELATIVES$0
M01 · FY2000 · RR